Claims
- 1. Compound of formula: ##STR187## in which A is S;
- B is C, and
- R.sub.3 is selected from the group consisting of H, C.sub.1 -C.sub.8 alkyl and halogen;
- Z.sub.1 is selected from the group consisting of C.sub.1 -C.sub.4 alkylene and phenylene,
- Z.sub.2 is C.sub.1 -C.sub.4 alkylene;
- W is NR.sub.1 R.sub.2, in which R.sub.1 is selected from the group consisting of H and C.sub.1 -C.sub.4 alkyl and R.sub.2 is COQ.sub.3 in which Q.sub.3 is C.sub.1 -C.sub.4 alkyl or W is selected from the group consisting of --CONQ.sub.1 Q.sub.2 ; --CNSQ.sub.1 Q.sub.2 in which Q.sub.1 and Q.sub.2 are independently selected from the group consisting of H and C.sub.1 -C.sub.4 alkyl; pyridyl, imidazolyl; and --COOQ.sub.5 in which Q.sub.5 is C.sub.1 -C.sub.5 alkyl;
- Ar.sub.1 is phenyl optionally substituted by one or more groups selected from halogen, C.sub.1 -C.sub.4 alkyl, alkoxy and thioalkoxy, hydroxy, carboxy, COOQ.sub.6, COSQ.sub.6, and CSOQ.sub.6 in which Q.sub.6 is C.sub.1 -C.sub.4 alkyl, carboxamido, cyano, amino, acetamido, nitro, or trifluoromethyl, or Ar.sub.1 is selected from the group consisting of an aromatic heterocycle thienyl, furyl, and indolyl,
- Ar.sub.2 is selected from the group consisting of a nitrogenous aromatic heterocycle quinolyl, isoquinolyl and pyridyl, optionally substituted by C.sub.1 -C.sub.3, alkyl or alkoxy or halogen;
- or a pharmaceutically acceptable salt, thereof.
- 2. Compound of formula: ##STR188## in which A is S;
- B is C, and
- R.sub.3 is selected from the group consisting of H, C.sub.1 -C.sub.8 alkyl and halogen;
- Z.sub.1 is selected from the group consisting of C.sub.1 -C.sub.4 alkylene and phenylene,
- Z.sub.2 is C.sub.1 -C.sub.4 alkylene;
- W is NR.sub.1 R.sub.2, in which R.sub.1 is selected from the group consisting of H and C.sub.1 -C.sub.4 alkyl and R.sub.2 is COQ.sub.3 in which Q.sub.3 is C.sub.1 -C.sub.4 alkyl or W is selected from the group consisting of --CONQ.sub.1 Q.sub.2 ; --CNSQ.sub.1 Q.sub.2 in which Q.sub.1 and Q.sub.2 are independently selected from the group consisting of H and C.sub.1 -C.sub.4 alkyl; pyridyl; imidazolyl; and --COOQ.sub.5 in which Q.sub.5 is C.sub.1 -C.sub.5 alkyl;
- Ar.sub.1 is selected from the group consisting of naphthyl, benzyl and cyclohexyl,
- Ar.sub.2 is selected from the group consisting of a nitrogenous aromatic heterocycle quinolyl, isoquinolyl and pyridyl, optionally substituted by C.sub.1 -C.sub.4 alkyl, alkoxy or halogen;
- or a pharmaceutically acceptable salt, thereof.
- 3. Compound according to claim 1 ##STR189## in which Z.sub.1 is selected from the group consisting of C.sub.1 -C.sub.4 alkylene and phenylene,
- Z.sub.2 is C.sub.1 -C.sub.3 alkylene,
- R.sub.3 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.8 alkyl,
- W is selected from the group consisting of pyridyl and imidazolyl,
- Ar.sub.1 is phenyl optionally bearing one or more substituents selected from the group consisting of halogen, C.sub.1 -C.sub.4 alkyl and alkoxy, nitro, trifluoromethyl and hydroxy,
- Ar.sub.2 is selected from the group consisting of quinolyl, isoquinolyl and pyridyl optionally substituted by C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and halogen;
- or a salt, thereof, with a pharmaceutically acceptable acid.
- 4. Compound according to claim 1 in which Ar.sub.1 is an at least ortho-substituted phenyl, or its salt.
- 5. Compound according to claim 1 in which Ar.sub.1 is phenyl without an ortho-substituent and R.sub.3 is C.sub.1 -C.sub.3 alkyl or its salt.
- 6. Compound according to claim 1 in which Ar.sub.2 is pyridyl.
- 7. Compound according to claim 1 in which Ar.sub.2 is selected from the group consisting of 2-pyridyl and 3-pyridyl, Z.sub.1 is C.sub.2 -C.sub.4 alkylene and W is NR.sub.1 R.sub.2.
- 8. Pharmaceutical composition comprising at least one compound according to claim 1 and at least one excipient.
- 9. Pharmaceutical composition comprising at least one compound according to claim 2 and at least one excipient.
- 10. A method for treating a disease associated with an excess of platelet-aggregating-factor-acether comprising administering to a patient in need thereof an effective amount of the compound of claim 1, in admixture with a pharmaceutically acceptable carrier.
- 11. A method for treating a disease associated with an excess of platelet-aggregating-factor-acether comprising administering to a patient in need thereof an effective amount of the compound of claim 2, in admixture with a pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
89 17491 |
Dec 1989 |
FRX |
|
Parent Case Info
This is a divisional of application Ser. No. 08/111,732, filed Aug. 25, 1993 U.S. Pat. No. 5,470,855 which is a continuation of application Ser. No. 07/743,309, filed Aug. 26, 1991, abandoned.
Foreign Referenced Citations (3)
Number |
Date |
Country |
0149884 |
Aug 1984 |
EPX |
0283390 |
Sep 1988 |
EPX |
880749 |
Jun 1953 |
DEX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
111732 |
Aug 1993 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
743309 |
Aug 1991 |
|